Evidence map›Paper›PMID 25682441›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2016

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Nozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata, Tomohiro Nishina, Shigenori Kadowaki, Eiji Shinozaki, Nozomu Machida, Satoshi Yuki, Akira Ooki, Shinya Kajiura and 7 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2017
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Nozomu FuseDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nofuse@east.ncc.go.jp.
Yasutoshi KubokiDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Takeshi KuwataDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, Shikoku Cancer Center, Matsuyama, Japan.
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Eiji ShinozakiGastroenterological Internal Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Nozomu MachidaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
Satoshi YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Akira OokiDepartment of Gastroenterology, Saitama Cancer Center Hospital, Ina, Japan.
Shinya KajiuraThe Third Department of Internal Medicine, University of Toyama, Toyama, Japan.
Tetsuo KimuraDepartment of Gastroenterology and Oncology, The University of Tokushima Graduate School, Tokushima, Japan.
Takeharu YamanakaDepartment of Biostatistics, National Cancer Center, Kashiwa, Japan.
Kohei ShitaraDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Akiko Kawano NagatsumaResearch Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takayuki YoshinoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Atsushi OchiaiResearch Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Atsushi OhtsuExploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
National Cancer Center Hospital East · JPAichi Cancer Center · JPHokkaido University Hospital · JPJapanese Foundation For Cancer Research · JPSaitama Cancer Center · JPShikoku Cancer Center · JPShizuoka Cancer Center · JPTokushima University · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and c-MET status are independent prognostic factors for advanced gastric cancer patients who received standard chemotherapy.

methodUnresectable or recurrent gastric or gastroesophageal junction cancer patients with histologically confirmed adenocarcinoma treated with S-1 plus cisplatin as first-line chemotherapy were eligible. Formalin-fixed paraffin-embedded tumor samples were examined for HER2, EGFR, and c-MET status using immunohistochemistry (IHC). Additionally, gene amplification was examined using fluorescent in situ hybridization (FISH) for HER2. Positivity was defined as an IHC score of 3+ or an IHC score of 2+/FISH positive for HER2, and an IHC score of 2+ or 3+ for both EGFR and c-MET.

resultsOf the 293 patients from nine institutions, 43 (15%) were HER2 positive, 79 (27%) were EGFR positive, and 120 (41%) were c-MET positive. Ten patients (3%) showed positive co-expression of HER2, EGFR, and c-MET. After a median follow-up time of 58.4 months with 280 deaths, there was no significant difference in overall survival (OS) in terms of HER2 and EGFR status. However, there was a significant difference in OS between c-MET-positive and c-MET-negative patients [median, 11.9 months vs 14.2 months; hazard ratio, 1.31 (95% confidence interval, 1.03-1.67); log-rank P = 0.024]. Multivariate analysis also showed that c-MET positivity was still a prognostic factor for OS [hazard ratio, 1.30 (95% confidence interval, 1.02-1.67); P = 0.037].

conclusionsThe study suggested that c-MET-positive status had poor prognostic value. These data could be used as the basis for future clinical trials for targeting agents for advanced gastric cancer patients.

Indexed as

AdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCisplatinDrug CombinationsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsEsophageal NeoplasmsEsophagogastric JunctionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedOxonic AcidBiomarkers, TumorCisplatinDrug CombinationsEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsOxonic AcidProto-Oncogene Proteins c-metS 1 (combination)Tegafurc-METEpidermal growth factor receptorGastric cancerGastroesophageal junction cancerHuman epidermal growth factor receptor 2

Identifiers

PMID25682441
OpenAlexW1996452689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.